3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow AngioLab, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis ALH-L1005 600mg/day, ALH-L1005 1,200mg/day, Placebo - Chronic Periodontitis | Phase 2 | Completed | AngioLab, Inc. | 117 | 2020-07-16 | 2022-08-11 |
| A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH Placebo oral tablet, ALS-L1023 1,200mg, ALS-L1023 1,800mg - Nonalcoholic Steatohepatitis | Phase 2 | Completed | AngioLab, Inc. | 60 | 2019-12-04 | 2022-08-11 |
| Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD ALS-L1023, Ranibizumab, Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | AngioLab, Inc. | 126 | 2018-12-07 | 2022-08-11 |
Chronic Periodontitis (1) · Macular Degeneration (1) · Non-alcoholic Fatty Liver Disease (1) · Periodontitis (1)
ALS-L1023 (2) · Ranibizumab (1)
South Korea (3)
Dae Won Jun, Ph. D. (1) · SeWoong Kang (1)